Bone health in HIV infection

British Medical Bulletin

Volumn 92, Issue 1, 2009, Pages 123-133

  Pollock, Emily ^a   Klotsas, Angelos Emmanouil ^b   Compston, Juliet ^a   Gkrania Klotsas, Effrossyni ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LUTON AND DUNSTABLE HOSPITAL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

AIDS; Antiretroviral; Bisphosphonates; Bone mineral density; Fracture; HIV; Osteoporosis; Vitamin D

Indexed keywords

ALENDRONIC ACID; ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; EFAVIRENZ; IBANDRONIC ACID; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; PLACEBO; PROTEINASE INHIBITOR; RISEDRONIC ACID; RNA DIRECTED DNA POLYMERASE INHIBITOR; VITAMIN D; ZIDOVUDINE; ZOLEDRONIC ACID;

BODY MASS; BONE; BONE DENSITY; BONE DEVELOPMENT; BONE DISEASE; BONE REMODELING; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAW OSTEONECROSIS; LANGUAGE; LIFESTYLE MODIFICATION; MONOTHERAPY; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SMOKING CESSATION; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; HIV INFECTIONS; HUMANS; LIFE STYLE; OSTEOPOROSIS; RISK FACTORS;

EID: 72049117149     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldp037     Document Type: Review

References (48)

1. Morse CG, Kovacs JA (2006) Metabolic and skeletal complications of HIV infection-the price of success. JAMA, 296, 844-854.
2. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int, 17, 1726-1733.
3. Health Protection Agency (HPA) (2008) HIV in the United Kingdom. London.
4. Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS, 20, 2165-2174.
5. Triant VA, Brown TT, Lee H, Grinspoon SK (2008) Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab, 93, 3499-3504.
6. Singh K, Moyle GJ (2006) Bone mineral abnormalities in persons with HIV infection: signal or noise? AIDS Read, 16, 407-10-413-418
7. Amorosa V, Tebas P (2006) HIV/AIDS bone disease and HIV infection. Clin Infect Dis, 42, 108-114.
8. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE (2006) HIV infection and bone mineral density in middle-aged women. Clin Infect Dis, 42, 1014-1020.
9. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE (2007) Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS, 21, 617-623.
10. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N et al. (2008) Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS, 22, 395-402.
11. Jones S, Restrepo D, Kasowitz A, Korenstein D, Wallenstein S, Schneider A et al. (2008) Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int, 19, 913-918.
12. Cassetti I, Madruga JV, Suleiman J et al. (2007) The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials, 8, 164-172. (Pubitemid 47121761)
13. Bolland MJ, Grey AB, Gamble GD, Reid IR (2007) Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab, 92, 4522-4528.
14. Rivas P, Gógolas M, Garcia-Delgado R, Diaz-Curie M, Goyenechea A, Fernandez-Guerrero M (2008) Evolution of bone mineral density in AIDS patients on treatment with zidovudine/ lamivudiine plus abacavir or lopinavir/ritonavir. HIV Med, 9, 89-95.
15. Dolan SE, Kanter JR, Grinspoon S (2006) Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab, 91, 2938-2945.
16. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL et al. (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleo-side reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS, 27, 817-824.
17. McComsey GA, Lore V, O'Riordan M et al. (2008) Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis, 46, 1290-1296.
18. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA, 292, 191-201.
19. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA (2009) Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr, 51, 554-561.
20. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC et al. (2009) Continuous antire-troviral therapy decreases bone mineral density. AIDS, 23, 1519-1529.
21. Compston J (2001) Sex steroids and bone. Physiol Rev, 81, 419-447.
22. Serrano S, Marinoso ML, Soriano JC, Rubies-Prat J, Aubia J, Coll J et al. (1995) Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone, 16, 185-191.
23. Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts and prospects. J Clin Invest, 115, 3318-3325.
24. Gibellini D, De Crignis E, Ponti C, Cimatti L, Borderi M, Tschon M et al. (2008) HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol, 80, 1507-1514.
25. Gibellini D, Borderi M, De Crignis E, Cicola R, Vescini F, Caudarella R et al. (2007) RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol, 79, 1446-1454.
26. Chirch LM, Feiner J, Go R, Mynarcik D, McNurlan M, Gelato M et al. (2006) Osteopenia in patients with HIV infection is not associated with elevated sTNFR2 levels. Clin Infect Dis, 43, 1084-1085.
27. Villamor E (2006) A potential role for vitamin D on HIV infection? Nutr Rev, 64, 226-233.
28. Pan G, Yang Z, Ballinger SW, McDonald JM (2006) Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann N Y Acad Sci, 1068, 297-308.
29. Malizia AP, Vioreanu MH, Doran PP, Powderly WG (2007) HIV1 protease inhibitors selectively induce inflammatory chemokine expression in primary human osteoblasts. Antiviral Res, 74, 72-76.
30. Tran H, Robinson S, Mikhailenko I, Strickland DK (2003) Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. J Lipid Res, 44, 1859-1869.
31. Carr A, Miller J, Eisman JA, Cooper DA (2001) Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS, 15, 703-709.
32. Gyllensten K, Josephson F, Lidman K, Saaf M (2006) Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. AIDS, 20, 1906-1907.
33. McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B et al. (2007) Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS, 21, 2473-2482.
34. Poole K, Compston JE (2006) Osteoporosis and its management. Br Med J, 333, 1251-1256.
35. Recker RR, Lewiecki EM, Miller PD, Reiffel J (2009) Safety of bisphosphonates in the treatment of osteoporosis. Am J Med, 122(Suppl 2), S22-S32.
36. Seeman E (2009) To stop or not to stop, that is the question. Osteoporos Int, 20, 187-195.
37. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma, 22, 346-350.
38. Reid I (2009) Osteonecrosis of the jaw: who gets it, and why? Bone, 44, 4-10.
39. Silverman SL, Landesberg R (2009) Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med, 122(Suppl 2), S33-S45.
40. Lin D, Rieder MJ (2007) Interventions for the treatment of decreased bone mineral density associated with HIV infection. Cochrane Database Syst Rev, CD005645.
41. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB et al. (2007) Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab, 92, 1283-1288.
42. Huang J, Meixner L, Fernandez S, McCutchan JA (2009) A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS, 23, 51-57.
43. Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK (2001) Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab, 86, 2020-2026.
44. Rodriguez M, Daniels B, Gunawardene S, Robbins GK (2009) High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses, 25, 9-14.
45. van den Bout-van den Beukel CJ, van den Bos M, Oyen WJ, Hermus AR, Sweep FC, Tack CJ et al. (2008) The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med, 9, 771-779.
46. Prior J, Burdge D, Maan E, Milner R, Hankins C, Klein M et al. (2007) Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int, 18, 1345-1353.
47. NICE N.I.f.H.a.C.E (2005) TA87 Osteoporosis-Secondary Prevention: Guidance. London: National Institute for Health and Clinical Excellence.
48. Negredo E, Martinez E, Cinquegrana D, Estany C, Clotet B (2007) Therapeutic management of bone demineralization in the HIV-infected population. AIDS, 21, 657-663.